RE:RE:RE:RE:TH2101There is still a job offer on their website drom April 15 for a drug discovery scientist. These are the first lines of the offer:
Under the supervision of the Manager, Chemistry, the Drug Discovery Scientist is responsible for managing a variety of activities, including the synthesis and purification of new anti-cancer molecules,
So it is pretty clear that they are in the process of developping the SORT1 platform. Also, the recent job offer for a preclinical project manager is in line with the drud discovery scientistt job offer. After synthesizing a new PDC, you need people qualified to test it in vitro, then in vivo (in animal models). So they are clearly working on that at every levels of the chain. As I said before, it is likely that TH2101 has already been tested in vitro and probably some in vivo testing as well. The fact that they put this new information in their new presentation is a hint about things to come. Remember how, in previous versions of the corporate presentation, oncology was gaining ground. Disclosing the TH2101 info follows the same logic. First a hint, then, a few months later, they come with the "piece de resistance".